Mangoceuticals Reports Revenue Increase in Q2 2025 but Significant Net Loss

Mangoceuticals, Inc. reported a revenue of $168,109 for the three months ended June 30, 2025, reflecting a slight increase from $163,163 in the same period of the previous year. However, the company experienced a decline in total revenue for the six months ended June 30, 2025, with figures dropping to $277,415 from $377,258 in the prior year. The decrease in revenue for the six-month period was attributed to challenges related to the transition to a new telehealth platform. The cost of revenues also decreased, amounting to $18,815 for the second quarter of 2025 compared to $29,665 in the same quarter of 2024, primarily due to reduced shipping expenses and lower costs associated with third-party doctor visits.

The company reported a significant net loss of $5,415,820 for the second quarter of 2025, compared to a net loss of $2,391,319 in the same quarter of 2024. This increase in loss was largely driven by higher general and administrative expenses, which rose to $1,245,360 from $850,704 year-over-year, as well as a substantial increase in stock-based compensation, which totaled $3,120,445 in the latest quarter. For the six-month period, the net loss was $10,255,309, up from $4,758,936 in the prior year, reflecting ongoing operational challenges and increased expenditures.

In terms of strategic developments, Mangoceuticals has been active in expanding its product offerings and operational capabilities. The company has entered into several agreements, including a Master Distribution Agreement with Propre Energie, Inc. for plant-based formulations and a similar agreement with Navy Wharf, Ltd. for a nutraceutical product. However, the Navy Wharf agreement was rescinded in July 2025. Additionally, the company has been involved in acquiring intellectual property, including patents related to respiratory illness prevention technology, and is conducting Phase II clinical trials for these products.

Operationally, Mangoceuticals has seen an increase in customer engagement, with a notable rise in the number of users for its MangoRx and PeachesRx products. The company has also expanded its employee headcount to support its growth strategy, which includes enhancing its telemedicine platform and marketing efforts. As of June 30, 2025, the company reported total assets of $20,842,828 and total liabilities of $1,600,945, resulting in a working capital deficit of approximately $1.48 million.

Looking ahead, Mangoceuticals anticipates the need for additional funding to support its operations and growth initiatives. The company plans to explore various financing options, including equity and debt offerings, to ensure it can continue its business operations and execute its strategic plans. The management has expressed concerns about the ability to secure necessary funding on favorable terms, which could impact the company's future growth and operational capabilities.